Abstract
This study was undertaken to determine the prevalence and correlates of cognitive impairment (CI) and neuropsychiatric symptoms (NPS) in early, untreated patients with Parkinson's disease (PD). Background: Both CI and NPS are common in PD and impact disease course and quality of life. However, limited knowledge is available about cognitive abilities and NPS. Methods: Parkinson's Progression Markers Initiative (PPMI) is a multi-site study of early, untreated PD patients and healthy controls (HCs), the latter with normal cognition. At baseline, participants were assessed with a neuropsychological battery and for symptoms of depression, anxiety, impulse control disorders (ICDs), psychosis, and apathy. Results: Baseline data of 423 PD patients and 196 HCs yielded no between-group differences in demographic characteristics. Twenty-two percent of PD patients met the PD-recommended screening cutoff for CI on the Montral Cognitive Assessment (MoCA), but only 9% met detailed neuropsychological testing criteria for mild cognitive impairment (MCI)-level impairment. The PD patients were more depressed than HCs (P
Original language | English (US) |
---|---|
Pages (from-to) | 919-927 |
Number of pages | 9 |
Journal | Movement disorders : official journal of the Movement Disorder Society |
Volume | 30 |
Issue number | 7 |
DOIs | |
State | Published - Jun 1 2015 |
Keywords
- Anxiety
- Apathy
- Cognition
- Depression
- Impulse control disorder
- Parkinson's disease
- Psychosis
ASJC Scopus subject areas
- Clinical Neurology
- Neurology